

Clarification of warrants resolved at the Annual General Meeting

Yesterday, on May 28, 2018, the Annual General Meeting was held in 2cureX AB (publ). The company hereby publishes a clarification regarding the exercise period of the warrants decided upon by the AGM.

Warrant program directed to Jørgen Drejer, Board member 2cureX AB

Jørgen Drejer is entitled to subscribe for 40,000 warrants, entitling to subscribe for a total of 40,000 new shares. Subscription of warrants shall take place no later than 1 June 2018. The exercise period is 28 May - 28 September 2021. The subscription price per share is calculated as the average of the closing price of the company's shares on NASDAQ Stockholm First North on each trading day during the period May 8, 2018 through May 28 2018 (both days included) with an addition of 12%.

Warrant program directed to Povl-André Bendz, Chairman of the Board 2cureX AB

Povl-André Bendz is entitled to subscribe for 80,000 warrants, entitling to subscribe for a total of 80,000 new shares. Subscription of warrants shall take place no later than 1 June 2018. The exercise period is 28 May - 28 September 2021. The subscription price per share is calculated as the average of the closing price of the company's shares on NASDAQ Stockholm First North on each trading day during the period May 8, 2018 through May 28 2018 (both days included) with an addition of 12%.

Warrant program directed to Jürgen Kupper, CEO for 2cureX GmbH

Jürgen Kupper is entitled to subscribe for 160,000 warrants, entitling to subscribe for a total of 160,000 new shares. Subscription of warrants shall take place no later than 1 June 2018. The exercise period is 28 May - 28 September 2020. The subscription price per share is calculated as the average of the closing price of the company's shares on NASDAQ Stockholm First North on each trading day during the period May 8, 2018 through May 28 2018 (both days included) with an addition of 12%.

Warrant program directed to Maarten van der Linde, CBO for 2cureX AB and 2cureX GmbH

Maarten van der Linde is entitled to subscribe for 80,000 warrants, entitling to subscribe for a total of 80,000 new shares. Subscription of warrants shall take place no later than 1 June 2018. The exercise period is 1 April - 1 August 2021. The subscription price per share is calculated as the average of the closing price of the company's shares on NASDAQ Stockholm First North on each trading day during the period May 8, 2018 through May 28 2018 (both days included) with an addition of 12%.

Certified Adviser

Sedermøra Fondkommission is the Certified Adviser of 2cureX.

For more information about 2cureX:

Ole Thastrup, CEO;
E-mail: ot@2cureX.com
Phone: +45 22 11 53 99;
URL: www.2curex.com

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient's tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.

IndiTreat® is currently being clinically validated in colorectal and ovarian cancer.

The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol "2CUREX").